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THE ACUTE EFFECTS OF PURIFIED CRYSTALLINE PITUITARY GROWTH
HORMONE IN NORMAL HUMAN BEINGS*
The ability of purified crystalline preparations obtained from the anterior
pituitary to produce growth in hypophysectomized animals has been estab-
lished repeatedly.3"' The effectiveness of a given preparation can be demon-
strated by its ability to produce linear growth" or to produce a positive
balance of nitrogen." The production of an increased epiphyseal width is
also considered evidence of growth-promoting activity,' although this effect
has also been reported as a result of the administration of insulin" or glu-
cagon." In human beings, the production of growth or of epiphyseal changes
cannot easily be studied, and most investigations of the effects of the hor-
mone have therefore been confined to balance experiments. Attempts to
produce a positive nitrogen balance in normal, diabetic, or hypopituitary
human patients have been unsuccessful"""" or incompletely reported."'
The difficulties of conducting accurate balance studies in human beings are
so great that only relatively large changes can be measured. Consequently,
physiologically significant alterations may have been produced in human
experiments, but the effect may not have been recognized because of the
grossness of the technique. The available preparations of growth hormone
have also usually produced untoward effects after several days of admin-
istration to human subjects, so that the anabolic actions may have been
obscured by the side effects such as fever, nausea, and anorexia.
In addition to its well-established effects in promoting growth, the
hormone also produces certain acute alterations in the metabolism which
can be detected in relatively short-term experiments in animals. For exam-
ple, the hormone causes an acute fall of blood glucose in intact rats' and
dogs,' a fall of plasma a-amino nitrogen in rats",7",' and in the blood amino
nitrogen of cats," and a rise of ketone bodies of rats.""" In hypophysec-
tomized rats, a rise of plasma inorganic phosphate occurs after the admin-
istration of growth hormone." Anti-insulin and diabetogenic properties may
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also manifest themselves after short periods of treatment in animals.9 7
Since these alterations are probably linked in some way with the growth-
promoting effect of the hormone,' and since it seemed likely that the acute
changes would be easier to demonstrate in human subjects than long-term
changes of nitrogen balance, attempts were made to reproduce in human
beings some of the metabolic effects of the acute administration of growth
hormone in experimental animals.
METHODS
The subjects consisted of 13 volunteers who were either entirely normal or were
convalescing from a minor acute illness. The experiments were conducted after an
overnight fast, with the subjects lying at ease on a bed in a quiet room. All venipunc-
tures were made under epinephrine-free procaine local anesthesia. In most cases sam-
ples were withdrawn from a Cournand needle set in place in an antecubital vein before
the beginning of the experiment so that repeated venipunctures were avoided. No
sedatives were used.
The growth hormone* was prepared according to the method of Wilhelmi et al.'7
and was supplied in lyophilized form in sterile bottles containing 25 mg. each. The
contents of each bottle were dissolved in five ml. of five per cent sodium bicarbonate in
distilled water. In ten cases the dissolved preparation was added to 200 ml. of physio-
logical saline which was injected by slow intravenous drip over a period of 30 or 60
minutes. In three instances, the hormone was diluted to 1,000 or 1,500 ml. and injected
over a period of 16 to 24 hours. The solution prepared in this manner was colorless and
opalescentanddidnotproduce either subjective or objective reactions in our volunteers,
except for mild anorexia after 12 hours of infusion in one case.
In the short-term experiments, blood samples were drawn immediately before the
beginning of the injection and as it ended. Additional samples were drawn at hourly
intervals up to four hours after the beginning of the experiment. When prolonged
infusions were used, samples were drawn immediately before starting the experiment,
before each meal, as the injection was completed, and 24 hours after the beginning of
the injection. The blood was deproteinated immediately by the appropriate method,
and analyses were performed within 36 hours. Glucose was determined by the iodo-
metric titration method of Somogyi,' blood ketones by the method of Greenberg and
Lester,' slightly modified, a-amino nitrogen according to the method of Frame and
Russell,'"0 and inorganic phosphate by the technique of Fiske and Subbarow."
In some cases attempts were made to show an effect of the growth hormone on the
glucose or insulin tolerance tests. These tests were performed 24 hours before and
24 hours after the start of the growth hormone infusion. Insulin tolerance was tested
by the intravenous injection of 0.1 unit of crystalline insulin per kilogram of body
weight. Glucose tolerance was measured after the intravenous injection of 25 grams of
glucose over a period of about one minute. Both tests were followed for about an hour.
* Kindly supplied by Dr. L. Mitchell, Frank W. Horner, Ltd., Montreal, Canada,
as Lot No. 20-1-2-J-51.
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RESULTS
The experimental results of the acute injections are set forth in Tables
1 and 2. When given over a period of 30 to 60 minutes, one to three mg./kg.
of growth hormone failed to affect the concentrations of glucose, a-amino
nitrogen, or phosphate in any consistent fashion. The effect of growth hor-
mone on these blood constituents was not different from the effect of saline.
EFFECT OF GROWTH HORMONE ON
INSULIN AND GLU COSE TOLERANCE TESTS
FIG. 1. The effects of intravenously administered purified anterior pituitary growth
hormone on the glucose and insulin tolerance. The broken line represents the test
before the hormone was given, and the solid line is the curve obtained 24 hours after
starting the hormone injection.
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Growth hormone consistently caused a rise of the blood ketone body con-
centration, whereas in the two control subjects where this analysis was
performed no change of blood ketones occurred. Observations of hemato-
crits and plasma proteins during the growth hormone injection showed that
no significant hemodilution had occurred.
TABLE 4. BLOOD GLUCOSE CONCENTRATION OF NORMAL PERSONS
NOT SUBJECT TO ENDOCRINE MANIPULATIONS
Blood glucose concentration
mg./100 ml.
Name
Jw
HB
FW
WG
AK
ww
AF
RK
PW
GR
AD
CM
Jw
Pre-breakfast
63
67
68
61
65
73
74
78
54
60
83
114
117
Pre-supper
71
70
67
66
82
88
54
51
70
59
70
65
57
Change
+8
+3
-1
+5
+17
+15
-20
-27
+16
-1
-13
9
-60
-8.2 +6.8*
* Mean + standard error
During the course of the prolonged intravenous infusions of growth
hormone, there was a consistent rise of blood glucose concentration (Table
3). This rise is higher than is seen in normal individuals" (Table 4). More-
over, in two of the three cases, the postabsorptive blood glucose concentra-
tion 24 hours after starting the injection was significantly higher than the
pre-injection concentration. Although there was some rise of blood ketone
bodies, this was less pronounced than in the subjects who received com-
parable doses of hormone in a much shorter period. The changes of a-amino
nitrogen are difficult to evaluate, since the plasma concentration of this
group of substances is reduced by insulin or glucose, and raised by feeding
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protein, so that any type of change might occur during the course of the
day as a result of feeding. The fall of inorganic phosphate probably has a
similar explanation.
Following the administration of growth hormone there was no convincing
change of the shape of the glucose or insulin tolerance curves, although the
fasting levels after the hormone tended to be higher, so that the curves were
sometimes parallel rather than superimposed (Fig. 1). In one case (F.L.)
the glucose tolerance appeared to have been somewhat impaired by growth
hormone, but this was difficult to interpret, since technical difficulties made
it necessary to reduce the amount injected to only 17.5 gm. and to shorten
the time of observation. There was no change in the response of inorganic
phosphate to insulin or glucose after the administration of growth hormone.
DISCUSSION
Previous attempts to demonstrate an effect of growth hormone in human
beings have usually depended on studies of the nitrogen balance carried on
over a long period of time. The doses of hormone were frequently rather
small, and the preparations were often somewhat toxic. Under these cir-
cumstances it is not surprising that most investigators have failed to find
any of the anticipated metabolic effects.2 0" 283 In a few cases brief reports
have appeared claiming the production of a positive nitrogen balance with
various growth preparations, but unfortunately these experiments have not
yet been published in sufficient detail to permit evaluation of the data.8'
In two recent studies, however, definite effects of growth hormone in
human beings appear to have been well documented. Carballeira, Elrick,
and Browne7 showed that the blood amino acid concentration fell faster
after the intravenous injection of amino acids if the subjects had received
growth hormone. Moreover, less amino acid nitrogen appeared in the urine
after growth hormone treatment. These data were interpreted as indicating
that growth hormone promoted the storage of amino acids in the tissues.
The differences reported are small, but they are consistent and probably
significant. These authors also reported a rise of blood glucose and ketone
bodies after the injection of growth hormone; however, since they never
injected the hormone without also giving amino acids, it is difficult to
determine the significance of these changes.
Kinsell et al.'8 have recently reported that the daily intravenous injection
of 100 mg. of growth hormone over a 24-hour period for six days in a dia'
betic patient on a constant dose of insulin resulted in an increased excretion
of glucose in the urine. There was also a rise of ketone bodies, but no con-
sistent change of blood glucose occurred.
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The present studies show that the acute intravenous injection of large
amounts of the hormone regularly produces ketosis, but has no other detect-
able effects. When comparable amounts of the hormone are injected slowly
over 16 to 24 hours, the production of ketosis is not marked, but a definite
increase of blood glucose concentration does occur. This effect does not
appear to be reflected in a change of glucose or insulin tolerance.
The pattern of metabolism induced by growth hormone in experimental
animals has been well established. Protein is spared from conversion to
carbohydrate or fat, or oxidation for energy, and is deposited as new proto-
plasm.'9 Carbohydrate is likewise spared, both as glycogen,'9 and by virtue
of the reduced carbohydrate metabolism, resulting, in its most florid form,
in diabetes mellitus.'9" Although the glycogenic effect may be partially
antagonized by the release of glucagon, as postulated by Bornstein et al.,'
Young,"9 and Foa et al.,"' and the diabetogenic effect combatted by the
release of insulin,6"" these adjustments fail to prevent the development of a
depressed rate of carbohydrate utilization.'
If protein and carbohydrate become less readily available as energy
sources, an increase in fat catabolism must make up the deficit. It is there-
fore not surprising that growth hormone has been found to cause a
mobilization of tissue lipids to the liver'9""' via the blood,5"' presumably as
a preliminary to increased fat oxidation. As the breakdown of fat increases,
ketosis occurs, probably because the load of two-carbon fragments accumu-
lating in the liver exceeds the capacity of the hepatic enzyme systems to
oxidize them directly.
It is of interest that ketosis was produced so easily in our subjects,
whereas other changes such as alterations of the plasma a-amino nitrogen,
blood glucose, or serum phosphate could not be demonstrated acutely. At
least two possible explanations may be considered for this discrepancy. The
dose may have been too small to produce the nitrogen or carbohydrate
effects, or the time of observation may have been too short to permit them
to appear. In dogs, ketosis and hyperlipemia occur within a few hours after
the administration of the hormone, whereas insulin or glucose tolerance
alterations require a much longer period of treatment.'m Perhaps the same
is true of man. In either case, whether because of too little hormone or too
little time, it is difficult to escape the conclusion that the shift to a high-fat
metabolic pattern is the earliest observed change produced by the hormone.
If this is the case, the emphasis on carbohydrate and protein in the pre-
ceding discussion may have been incorrect. Instead of considering the
ketosis a result of changes of protein and carbohydrate metabolism, it might
be more nearly correct to view the shift to a high-fat metabolic substrate as
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the basic alteration which precedes and facilitates the more spectacular
protein and carbohydrate effects. The observations of Greenbaum' that the
hormone-induced growth ceases when body fat depots are exhausted
supports this viewpoint.
This interpretation is apparently in conflict with the observations that the
lipid-mobilizing ("adipokinetic") action of pituitary extracts is not neces-
sarily associated with the growth hormone fraction.28'"' It is possible, how-
ever, that the fat-mobilizing activity of the pituitary may reside in several
different fractions. In any case, it is difficult to see how a material with the
metabolic properties ascribed to the purified preparations of growth
hormone now available could fail to exert a fat-catabolism-promoting effect.
SUMMARY
The intravenous injection of purified crystalline growth hormone in doses
of one to five mg./kg. over periods of 30 minutes to 24 hours failed to alter
the plasma amino acid concentration, the serum phosphate, or the insulin or
glucose tolerance of normal human volunteers. When the hormone was
given rapidly, ketosis developed, but when it was given slowly the ketogenic
effect was less marked and a rise of blood glucose occurred.
Since ketosis appeared earlier and more consistently than any other
change, and since alterations of fat metabolism occur in animals before
changes in carbohydrate or protein metabolism can be demonstrated, it is
suggested that the basic effect of growth hormone may be to promote the
use of fat as the major metabolic substrate. This would reduce the demand
for protein and carbohydrate as sources of energy and facilitate their storage
as protoplasm and glycogen, respectively.
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